Late presentation of RPE65 retinopathy in three siblings
Magliyah, Moustafa ; Saifaldein, Amjad Ameen and Schatz, Patrik LU
(2020)
In Documenta Ophthalmologica
140(3).
p.289-297
- Abstract
Purpose: Gene therapy for RPE65 retinopathy has been recently approved. The purpose of this study was to assess retinal structure and function in 3 siblings presenting with late-stage RPE65 retinopathy and to assess the unmet need for such therapy in Saudi Arabia. Methods: Search of the retinal dystrophy registry at King Khaled Eye Specialist Hospital and clinical examination including multimodal retinal imaging, full-field electroretinography (ERG), dark adapted full-field stimulus sensitivity thresholds, and molecular genetic testing in 3 patients. Results: Nine (9) patients were identified with biallelic RPE65 mutations, corresponding to a prevalence rate of 9/187 = 5% among early onset retinal dystrophies. Of these, 3 siblings (2... (More)
Purpose: Gene therapy for RPE65 retinopathy has been recently approved. The purpose of this study was to assess retinal structure and function in 3 siblings presenting with late-stage RPE65 retinopathy and to assess the unmet need for such therapy in Saudi Arabia. Methods: Search of the retinal dystrophy registry at King Khaled Eye Specialist Hospital and clinical examination including multimodal retinal imaging, full-field electroretinography (ERG), dark adapted full-field stimulus sensitivity thresholds, and molecular genetic testing in 3 patients. Results: Nine (9) patients were identified with biallelic RPE65 mutations, corresponding to a prevalence rate of 9/187 = 5% among early onset retinal dystrophies. Of these, 3 siblings (2 male and 1 female) with RPE65 retinopathy were assessed in detail, because of an unusual, late presentation. They were all over 30 years old at the time of their most recent visits and had non-recordable ERGs. The 2 male siblings presented with poor vision and paracentral loss of the inner segment ellipsoid (ISe) and focal attenuation of the outer nuclear layer (ONL) in the macula. On the other hand, the female sibling presented with 20/100 vision with preserved foveal ISe and intact ONL throughout the macula and significantly lower light sensitivity thresholds compared to her male siblings. A homozygous missense p.Arg91Trp mutation in RPE65 was identified in all. All patients were eligible for gene therapy, demonstrating a central retinal thickness of more than 100 microns on repeated examinations. Conclusions: RPE65 retinopathy seems to be relatively common on the Arabian peninsula, and in addition it may be underdiagnosed. To the best of our knowledge, this is the first detailed presentation, including multimodal retinal imaging and electrophysiological assessment, of such patients from this region. Patients with late presentation of RPE65 retinopathy may be eligible for gene therapy, in terms of remaining retinal function and structural preservation. The therapeutic window of such therapy remains to be determined.
(Less)
- author
- Magliyah, Moustafa
; Saifaldein, Amjad Ameen
and Schatz, Patrik
LU
- organization
- publishing date
- 2020-06
- type
- Contribution to journal
- publication status
- published
- subject
- keywords
- Gene therapy, Multimodal retinal imaging, RPE65
- in
- Documenta Ophthalmologica
- volume
- 140
- issue
- 3
- pages
- 9 pages
- publisher
- Springer
- external identifiers
-
- pmid:31925606
- scopus:85077703379
- ISSN
- 0012-4486
- DOI
- 10.1007/s10633-019-09745-z
- language
- English
- LU publication?
- yes
- id
- d5cf58f8-50e6-4692-b614-36400662cbb6
- date added to LUP
- 2020-01-29 16:10:18
- date last changed
- 2024-04-17 02:49:10
@article{d5cf58f8-50e6-4692-b614-36400662cbb6,
abstract = {{<p>Purpose: Gene therapy for RPE65 retinopathy has been recently approved. The purpose of this study was to assess retinal structure and function in 3 siblings presenting with late-stage RPE65 retinopathy and to assess the unmet need for such therapy in Saudi Arabia. Methods: Search of the retinal dystrophy registry at King Khaled Eye Specialist Hospital and clinical examination including multimodal retinal imaging, full-field electroretinography (ERG), dark adapted full-field stimulus sensitivity thresholds, and molecular genetic testing in 3 patients. Results: Nine (9) patients were identified with biallelic RPE65 mutations, corresponding to a prevalence rate of 9/187 = 5% among early onset retinal dystrophies. Of these, 3 siblings (2 male and 1 female) with RPE65 retinopathy were assessed in detail, because of an unusual, late presentation. They were all over 30 years old at the time of their most recent visits and had non-recordable ERGs. The 2 male siblings presented with poor vision and paracentral loss of the inner segment ellipsoid (ISe) and focal attenuation of the outer nuclear layer (ONL) in the macula. On the other hand, the female sibling presented with 20/100 vision with preserved foveal ISe and intact ONL throughout the macula and significantly lower light sensitivity thresholds compared to her male siblings. A homozygous missense p.Arg91Trp mutation in RPE65 was identified in all. All patients were eligible for gene therapy, demonstrating a central retinal thickness of more than 100 microns on repeated examinations. Conclusions: RPE65 retinopathy seems to be relatively common on the Arabian peninsula, and in addition it may be underdiagnosed. To the best of our knowledge, this is the first detailed presentation, including multimodal retinal imaging and electrophysiological assessment, of such patients from this region. Patients with late presentation of RPE65 retinopathy may be eligible for gene therapy, in terms of remaining retinal function and structural preservation. The therapeutic window of such therapy remains to be determined.</p>}},
author = {{Magliyah, Moustafa and Saifaldein, Amjad Ameen and Schatz, Patrik}},
issn = {{0012-4486}},
keywords = {{Gene therapy; Multimodal retinal imaging; RPE65}},
language = {{eng}},
number = {{3}},
pages = {{289--297}},
publisher = {{Springer}},
series = {{Documenta Ophthalmologica}},
title = {{Late presentation of RPE65 retinopathy in three siblings}},
url = {{http://dx.doi.org/10.1007/s10633-019-09745-z}},
doi = {{10.1007/s10633-019-09745-z}},
volume = {{140}},
year = {{2020}},
}